MW 224.3 Da, Purity >98%. Selective, ATP-competitive, irreversible IKKβ inhibitor (IC50 = 3-12 μM). Reduces iNOS induction. Shows anti-inflammatory effects in vivo. Orally active.
I-kappa-B kinase 2, I-kappa-B-kinase beta, IKK-beta, IKK2, IKKB_HUMAN, IMD15, IkBKB, Inhibitor of kappa light polypeptide gene enhancer in B cells, kinase beta, Inhibitor of nuclear factor kappa-B kinase subunit beta, NFKBIKB, Nuclear factor NF-kappa-B inhibitor kinase beta
MW 224.3 Da, Purity >98%. Selective, ATP-competitive, irreversible IKKβ inhibitor (IC50 = 3-12 μM). Reduces iNOS induction. Shows anti-inflammatory effects in vivo. Orally active.
Soluble in ethanol to 10 mM.
Soluble in DMSO to 100 mM.
Selective, ATP-competitive, irreversible IKKβ inhibitor (IC50 = 3-12 μM). Reduces iNOS induction. Shows anti-inflammatory effects in vivo. Orally active.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com